Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-THINc ESRD: BAY 2976217 (fesomersen) in hemodialysis patients
jRCT2031200303Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2021
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of fesomersen in end-stage kidney disease (ESKD) and thrombosis (4 arms), sponsored by Bayer. Primary endpoint: Incidence of major bleeding and clinically relevant non-major bleeding during the main treatment period. Started Jan 2021; status: completed.
02
Drugs
fesomersen
03
Conditions
end-stage kidney disease (ESKD)thrombosis
Beyond the preview
Go deeper on jRCT2031200303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200303.